Serum Leptin is not altered nor related to cognitive decline in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 3, 2015, Pages 809-813

  Teunissen, Charlotte E ^a   Van Der Flier, Wiesje M ^a,b   Scheltens, Philip ^b   Duits, Anneli ^a   Wijnstok, Nienke ^a,c   Nijpels, Giel ^a   Dekker, Jacqueline M ^a   Blankenstein, Rien M A ^a   Heijboer, Annemieke C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alzheimer's disease; atrophy; blood based biomarker; cognition; leptin; vascular dementia

Indexed keywords

LEPTIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; BRAIN ATROPHY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK FACTOR; BLOOD; BODY MASS; COGNITION DISORDERS; COMPLICATION; MENTAL HEALTH; NUCLEAR MAGNETIC RESONANCE IMAGING; SEX DIFFERENCE;

AGED; ALZHEIMER DISEASE; BODY MASS INDEX; COGNITION DISORDERS; FEMALE; HUMANS; LEPTIN; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; SEX FACTORS;

EID: 84922658431     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141503     Document Type: Article

References (19)

1. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N, Casadesus G (2010) Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 19, 1155-1167.
2. Paz-Filho G, Wong ML, Licinio J (2010) Leptin levels and Alzheimer disease. JAMA 303, 1478-1479.
3. Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S (2009) Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302, 2565-2572.
4. Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ (2011) Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis 24, 101-108.
5. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL,Tuomilehto J, Soininen H, NissinenA (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62, 1556-1560.
6. Inelmen EM, Sergi G, Coin A, Girardi A, Manzato E (2010) Anopen-ended question: Alzheimer's disease and involuntary weight loss: Which comes first? Aging Clin Exp Res 22, 192-197.
7. Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V (2012) Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 16, 472-477.
8. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B (2014) Biobanking of CSF: International standardization to optimize biomarker development. Clin Biochem 47, 288-292.
9. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, van EE, Scheltens P (2014) Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis 41, 313-327.
10. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
11. van 't RE, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM (2010) Relationship between A1C and glucose levels in the general Dutch population: The new Hoorn study. Diabetes Care 33, 61-66.
12. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55, 967-972.
13. Warren MW, Hynan LS, Weiner MF (2012) Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29, 151-157.
14. Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, Gawaz M, Stellos K, Laske C (2011) Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 6, e20286.
15. Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N (2014) Low plasma leptin in cognitively impaired ADNI subjects: Gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 11, 165-174.
16. Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, Biswas A, Basu D, Chakrabarti S (2014) Altered serum levels of adipokines and insulin in probable Alzheimer's disease. J Alzheimers Dis 41, 525-533.
17. Reijmer YD, van den Berg E, Dekker JM, Nijpels G, Stehouwer CD, Kappelle LJ, Biessels GJ (2012) Development of vascular risk factors over 15 years in relation to cognition: The Hoorn Study. J Am Geriatr Soc 60, 1426-1433.
18. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P,Wiste HJ,Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12, 207-216.
19. Bonda DJ, Stone JG, Torres SL, Siedlak SL, Perry G, Kryscio R, Jicha G, Casadesus G, Smith MA, Zhu X, Lee HG (2014) Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance. J Neurochem 128, 162-172.